NCT05867589 is a NA clinical trial of 68Ga/18F-FAPI-04 in Myocardial Fibrosis, sponsored by Nanjing First Hospital, Nanjing Medical University.

Who is sponsoring NCT05867589?

NCT05867589 is sponsored by Nanjing First Hospital, Nanjing Medical University.

What drugs are being tested in NCT05867589?

Interventions in NCT05867589: 68Ga/18F-FAPI-04.

What condition does NCT05867589 study?

NCT05867589 studies Myocardial Fibrosis.

Is NCT05867589 still recruiting?

NCT05867589 is currently status unknown. Last updated 22 May 2023.

Last reviewed 2023-05-22 · How we verify

NCT05867589

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Novel PET Tracer Gallium [68Ga]/ Fluorine [18F] -FAPI-04 in the Diagnosis of Cardiovascular Diseases

Status unknown NA Last updated 22 May 2023

What this trial tests

NA trial testing 68Ga/18F-FAPI-04 in Myocardial Fibrosis in 100 participants. Status unknown.

Timeline

1 May 2023

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	Nanjing First Hospital, Nanjing Medical University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	100
Start date	1 May 2023
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

68Ga/18F-FAPI-04 — full drug profile →

Conditions studied

Myocardial Fibrosis — all drugs for Myocardial Fibrosis →

Sponsor

Nanjing First Hospital, Nanjing Medical University

Who can join

Adults 18 to 85, any sex, with Myocardial Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety of fibroblast activating protein receptor imaging agent \[68Ga\]/ Fluorine \[18F\] -fibroblast activating protein inhibitor (68Ga/18F-FAPI-04) in clinical application and to verify its effectiveness in the diagnosis of cardiovascular diseases.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Evaluation of myocardial fibrosis and wall motion abnormality with <sup>68</sup>Ga-FAPI PET/MR in coronary heart disease.
Luo R, Zhao Z, Zhang C, Li RS, et al · · 2025 · cited 1× · PMID 40690085 · DOI 10.1186/s13550-025-01246-2

Verify or expand the search:

Other recruiting trials for Myocardial Fibrosis

Currently open trials in the same condition.

NCT07296081 — ⁶⁸Ga-FAPI PET/CT for Cardiac Fibrosis in Heart Failure · recruiting
NCT06994221 — Fibrosis Assessment in Myocardial Infarction-associated Ventricular Aneurysm · recruiting
NCT05912231 — Ultrahypofractionation and Normal Tissue Toxicity · NA · active not recruiting
NCT05302271 — Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia · Phase 1 · recruiting
NCT06619600 — Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardi · Phase 3 · active not recruiting

Other Nanjing First Hospital, Nanjing Medical University trials

Trials by the same sponsor.

NCT07349979 — PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy · NA · not yet recruiting
NCT07505056 — Jianpi Lishi Jiedu Granules for Prevention of Postoperative Recurrence in Colorectal Advanced Adenomas · Phase 3 · not yet recruiting
NCT07397234 — Thyroid Cartilage Plane VS Superior Laryngeal Nerve Space Block in Awake Tracheal Intubation · NA · not yet recruiting
NCT07455448 — Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study · completed
NCT07385885 — Ultrasound-guided Non-invasive Simulation in Anesthesia Residency Training · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05867589 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanjing First Hospital, Nanjing Medical University
Last refreshed: 22 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05867589.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing